ACHAOGEN, INC. (NASDAQ:AKAO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 14, 2017, the Company held its Annual Meeting of
Stockholders (the Annual Meeting). At the Annual Meeting, the
Companys stockholders voted on two proposals, each of which is
described in more detail in the Companys definitive proxy
statement on Schedule 14A filed with the Securities and Exchange
Commission on April 26, 2017. Only stockholders of record as of
the close of business on April 17, 2017, the record date for the
Annual Meeting, were entitled to vote at the Annual Meeting. As
of the record date, 35,848,030 shares of the Companys common
stock were outstanding and entitled to vote at the Annual
Meeting. The tabulation of the stockholder votes on each proposal
brought before the Annual Meeting is as follows:
|
1. |
The election of three directors to hold office until the |
|
Nominee |
For |
Withheld |
|
John C. Doyle |
26,042,728 |
1,857,683 |
|
Kent E. Lieginger, Pharm.D. |
26,346,836 |
1,553,575 |
|
Bryan E. Roberts, Ph.D. |
26,643,246 |
1,257,165 |
There were 6,019,248 broker non-votes for this proposal.
|
2. |
The ratification of the selection, by the Audit Committee |
|
For |
Against |
Abstain |
||
|
33,902,478 |
5,676 |
11,505 |
||
As a routine proposal under applicable rules, no broker non-votes
were recorded in connection with this proposal.
About ACHAOGEN, INC. (NASDAQ:AKAO)
Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.
